Direct Comparison of Risankizumab and Fumaric Acid Esters in Systemic–Therapy‐Naive Patients With Moderate to Severe Plaque Psoriasis: A Randomized Controlled Trial

British Journal of Dermatology ◽

10.1111/bjd.20481 ◽

2021 ◽

Author(s):

D. Thaçi ◽

K. Eyerich ◽

A. Pinter ◽

M. Sebastian ◽

K. Unnebrink ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Fumaric Acid ◽

Plaque Psoriasis ◽

Systemic Therapy ◽

Controlled Trial ◽

Severe Plaque Psoriasis ◽

Fumaric Acid Esters ◽

Randomized Controlled ◽

Acid Esters

Patient‐reported outcomes with risankizumab versus fumaric acid esters in systemic therapy‐naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.17109 ◽

2021 ◽

Author(s):

D Thaçi ◽

AM Soliman ◽

K Eyerich ◽

A Pinter ◽

M Sebastian ◽

...

Keyword(s):

Clinical Trial ◽

Fumaric Acid ◽

Plaque Psoriasis ◽

Systemic Therapy ◽

Patient Reported Outcomes ◽

Phase 3 ◽

Severe Plaque Psoriasis ◽

Fumaric Acid Esters ◽

Patient Reported ◽

Acid Esters

Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial

British Journal of Dermatology ◽

10.1111/bjd.15707 ◽

2017 ◽

Vol 177 (4) ◽

pp. 1024-1032 ◽

Cited By ~ 27

Author(s):

M. Sticherling ◽

U. Mrowietz ◽

M. Augustin ◽

D. Thaçi ◽

N. Melzer ◽

...

Keyword(s):

Fumaric Acid ◽

Plaque Psoriasis ◽

Prime Trial ◽

Severe Plaque Psoriasis ◽

Fumaric Acid Esters ◽

Randomized Controlled ◽

Systemic Treatments ◽

Acid Esters

Efficacy and safety of fumaric acid esters in young patients aged 10 to 17 years with moderate‐to‐severe plaque psoriasis – A randomised, double‐blinded, placebo‐controlled trial

British Journal of Dermatology ◽

10.1111/bjd.19747 ◽

2020 ◽

Author(s):

H. Hamm ◽

D. Wilsmann‐Theis ◽

A. Tsianakas ◽

T. Gambichler ◽

K. Taipale ◽

...

Keyword(s):

Fumaric Acid ◽

Plaque Psoriasis ◽

Controlled Trial ◽

Young Patients ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Fumaric Acid Esters ◽

Double Blinded ◽

Acid Esters

PPC 06 ( Tepilamide Fumarate), a novel fumaric acid ester, is efficacious in treating plaque psoriasis: Results from a phase 2b randomized controlled trial

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.3.supp.33 ◽

2019 ◽

Vol 3 ◽

pp. S33

Author(s):

Mark Lebwohl ◽

Leon Kircik ◽

Kristian Reich ◽

Sugar Munjal ◽

Srinivas Shenoy ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Fumaric Acid ◽

Plaque Psoriasis ◽

Acid Ester ◽

Controlled Trial ◽

Randomized Controlled ◽

Fumaric Acid Ester

Abstract not available.

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

British Journal of Dermatology ◽

10.1111/bjd.14164 ◽

2015 ◽

Vol 173 (6) ◽

pp. 1387-1399 ◽

Cited By ~ 201

Author(s):

C. Paul ◽

J. Cather ◽

M. Gooderham ◽

Y. Poulin ◽

U. Mrowietz ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Plaque Psoriasis ◽

Controlled Trial ◽

Phase Iii ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Phosphodiesterase 4 Inhibitor

Efficacy and safety of apremilast with or without topical or phototherapy: Subanalysis of the population with < PASI-75 in the ESTEEM 1 phase 3, randomized, controlled trial in patients with moderate to severe plaque psoriasis

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2016.02.963 ◽

2016 ◽

Vol 74 (5) ◽

pp. AB246 ◽

Cited By ~ 1

Keyword(s):

Randomized Controlled Trial ◽

Plaque Psoriasis ◽

Controlled Trial ◽

Efficacy And Safety ◽

Phase 3 ◽

Severe Plaque Psoriasis ◽

Randomized Controlled

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2015.05.013 ◽

2015 ◽

Vol 73 (3) ◽

pp. 400-409 ◽

Cited By ~ 287

Author(s):

Diamant Thaçi ◽

Andrew Blauvelt ◽

Kristian Reich ◽

Tsen-Fang Tsai ◽

Francisco Vanaclocha ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Plaque Psoriasis ◽

Controlled Trial ◽

Severe Plaque Psoriasis ◽

Randomized Controlled

Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: A phase IIIb, randomized, controlled trial

International Journal of Dermatology ◽

10.1111/j.1365-4632.2006.02777.x ◽

2006 ◽

Vol 45 (5) ◽

pp. 605-614 ◽

Cited By ~ 53

Author(s):

Kim A. Papp ◽

Reni Bressinck ◽

Scott Fretzin ◽

Bernard Goffe ◽

Steven Kempers ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Plaque Psoriasis ◽

Controlled Trial ◽

Severe Plaque Psoriasis ◽

Randomized Controlled ◽

Phase Iiib

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2015.03.049 ◽

2015 ◽

Vol 73 (1) ◽

pp. 37-49 ◽

Cited By ~ 273

Author(s):

Kim Papp ◽

Kristian Reich ◽

Craig L. Leonardi ◽

Leon Kircik ◽

Sergio Chimenti ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Plaque Psoriasis ◽

Controlled Trial ◽

Phase Iii ◽

Pde4 Inhibitor ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phosphodiesterase 4 ◽

Randomized Controlled

Faculty Opinions recommendation of Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725781037.793521633 ◽

2016 ◽

Author(s):

Gil Yosipovitch ◽

Leigh Nattkemper

Keyword(s):

Randomized Controlled Trial ◽

Plaque Psoriasis ◽

Controlled Trial ◽

Phase Iii ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Phosphodiesterase 4 Inhibitor